POP-OUT | CLOSE
 
 
ZANAMIVIR
 
ZMR is found in 19 entries
ZMR
  •   Chemical Component Summary   Hide
    Name ZANAMIVIR
    Identifiers 5-(acetylamino)-2,6-anhydro-3,4,5-trideoxy-4-[(diaminomethylidene)amino]-D-glycero-D-galacto-non-2-enonic acid
    (4S,5R,6R)-5-acetamido-4-(diaminomethylideneamino)-6-[(1R,2R)-1,2,3-trihydroxypropyl]-5,6-dihydro-4H-pyran-2-carboxylic acid
    Synonyms MODIFIED SIALIC ACID
    Formula C12 H20 N4 O7
    Molecular Weight 332.31 g/mol
    Type non-polymer
    Isomeric SMILES
    InChI
    InChI key ARAIBEBZBOPLMB-UFGQHTETSA-N
     
  •   Drug Info: DrugBank Hide
    DrugBank ID DB00558   (Stereoisomeric match)
    Name Zanamivir
    Groups
    • approved
    • investigational
    Description A guanido-neuraminic acid that is used to inhibit neuraminidase. [PubChem]
    Synonyms
    • (2R,3R,4S)-3-(acetylamino)-4-Carbamimidamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
    • 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid
    • 4-Guanidino-neu5ac2en
    • 5-(acetylamino)-2,6-Anhydro-4-carbamimidamido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid
    • 5-acetamido-2,6-Anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid
    • GANA
    • GNA
    • Modified sialic acid
    • Relenza
    • Zanamavir
    • ZANAMIVIR
    • ZMR
    [more]
    Brand names Relenza
    Affected organism
    • Influenza A virus
    • Influenza B virus
    Indication For the prevention and treatment of influenza A and B.
    Pharmacology Zanamivir, an antiviral agent, is a neuraminidase inhibitor indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients 7 years and older who have been symptomatic for no more than 2 days. Zanamivir has also been shown to significantly inhibit the human sialidases NEU3 and NEU2 in the micromolar range (Ki 3.7 +/-0.48 and 12.9+/-0.07 microM, respectively), which could account for some of the rare side effects of zanamivir.
    Mechanism of action The proposed mechanism of action of zanamivir is via inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release. By binding and inhibiting the neuraminidase protein, the drug renders the influenza virus unable to escape its host cell and infect others.
    Route of administration Respiratory (inhalation)
    Categories
    • Antiviral Agents
    • Enzyme Inhibitors
    ATC-Code J05AH01
    AHFS-Code 08:18.28
    CAS number 139110-80-8
    Targets
    Name Sequence search Pharmacological action Actions
    Neuraminidase   Search  yes inhibitor
    Sialidase-2   Search  unknown inhibitor
    Neuraminidase   Search  yes inhibitor
     
Ligand Image